Developments in the chemistry and biology of 1,2,3‐triazolyl‐C‐nucleosides
- 27 December 2023
- journal article
- review article
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (3) , e2300580
Abstract
In the last 50 years, nucleoside analogs have been introduced to drug therapy as antivirals for different types of cancer due to their interference in cellular proliferation. Among the first line of nucleoside treatment drugs, ribavirin (RBV) is a synthetic N‐nucleoside with a 1,2,4‐triazole moiety that acts as a broad‐spectrum antiviral. It is on the World Health Organization (WHO) list of essential medicines. However, this important drug therapy causes several side effects due to its nonspecific mechanism of action. There is thus a need for a continuous study of its scaffold. A particular approach consists of connecting d‐ribose to the nitrogen‐containing base with a C–C bond. It provides more stability against enzymatic action and a better pharmacologic profile. The coronavirus disease (COVID) pandemic has increased the need for more solutions for the treatment of viral infections. Among these solutions, remdesivir, the first C‐nucleoside, has been approved by the Food and Drug Administration (FDA) for clinical use against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It drew attention to the study of the C‐nucleoside scaffold. Different C‐nucleoside patterns have been synthesized over the years. They show many important activities against viruses and cancer cell lines. 1,2,3‐Triazolyl‐C‐nucleoside derivatives are a prolific and efficient subclass of RBV analogs close to the already‐known RBV with a C–C bond modification. These compounds are often prepared by alkynylation of the d‐ribose ring followed by azide‐alkyne cycloaddition. They are reported to be active against the Crimean‐Congo hemorrhagic fever virus and several tumoral cell lines, showing promising biological potential. In this review, we explore such approaches to 1,2,3‐triazolyl‐C‐nucleosides and their evolution over the years.Keywords
This publication has 63 references indexed in Scilit:
- Design, synthesis, and antiviral activity of new 1H-1,2,3-triazole nucleoside ribavirin analogsMedicinal Chemistry Research, 2013
- Synthesis of purine modified 2′-C-methyl nucleosides as potential anti-HCV agentsBioorganic & Medicinal Chemistry Letters, 2011
- Triazole-linked reduced amide isosteres: An approach for the fragment-based drug discovery of anti-Alzheimer’s BACE1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Janus-type AT nucleosides: synthesis, solid and solution state structuresOrganic & Biomolecular Chemistry, 2011
- Selective Modulation of DNA Polymerase Activity by Fixed‐Conformation Nucleoside AnaloguesAngewandte Chemie International Edition, 2010
- Huisgen Cycloaddition Reaction of C-Alkynyl Ribosides under Micellar Catalysis: Synthesis of Ribavirin AnaloguesThe Journal of Organic Chemistry, 2009
- Direct C-Glycosylation by Indium-Mediated Alkynylation on Sugar Anomeric PositionOrganic Letters, 2008
- A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal AlkynesAngewandte Chemie International Edition, 2002
- Synthesis and Antiviral Activity of 1,5-and 1,3-Dialkyl-1,2,4-triazoleC-Nucleosides Derived from 1-(Chloroalkyl)-1-aza-2-azoniaallene SaltsNucleosides and Nucleotides, 1999
- Synthesis of D-ribofuranosyl derivatives of methyl propiolate as C-nucleoside precursorsJournal of the Chemical Society, Chemical Communications, 1975